全部所有文章

UBI獲得美國NIH BioDefense機構支援發展其 SARS Immunodiagnostic Test的開發

UBI (United Biomedical, Inc) of Hauppauge, NY USA has been selected by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH), to further develop its synthetic peptide-based diagnostic test for SARS. UBI will receive $1.6 million under an NIAID Research Project Cooperative Agreement to identify marker peptides from the non-structural proteins of the SARS virus. These peptides will then be incorporated into the company's SARS test that detects antibodies against the SARS virus. That test already has diagnostic marker peptides from SARS virus structural proteins. The NIH funding is part of U.S. government policy to expand biodefense.

"We hope to use this opportunity to advance knowledge of the hidden pathways by which SARS is spread. An improved immunodiagnostic test will lead to more sensitive detection of infection and will aid public health authorities to prevent future outbreaks, whether naturally or intentionally introduced", said Dr. Chang Yi Wang, UBI Chief Executive Officer.

The already available UBI immunodiagnostic test for SARS was developed last year in a crash program by researchers at UBI (Hauppauge, NY) and UBI-Asia (Hsin Chu, Taiwan), in collaboration with National Taiwan University Medical School and Academia Sinica (Taiwan). The efficacy of this UBI test was recently reported in the September 2004 issue of Emerging Infectious Diseases, published by the US Centers for Disease Control and Prevention (CDC, Atlanta).
回上頁